These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 22699526)
21. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas. Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673 [TBL] [Abstract][Full Text] [Related]
22. Is FDG-PET/CT Useful for Diagnosing Pulmonary Metastasis in Patients with Soft Tissue Sarcoma? Hagi T; Nakamura T; Sugino Y; Matsubara T; Asanuma K; Sudo A Anticancer Res; 2018 Jun; 38(6):3635-3639. PubMed ID: 29848720 [TBL] [Abstract][Full Text] [Related]
23. Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma. Hurley C; McCarville MB; Shulkin BL; Mao S; Wu J; Navid F; Daw NC; Pappo AS; Bishop MW Pediatr Blood Cancer; 2016 Aug; 63(8):1381-6. PubMed ID: 27082077 [TBL] [Abstract][Full Text] [Related]
24. Lymph node standardized uptake values at pre-treatment Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776 [TBL] [Abstract][Full Text] [Related]
25. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Denecke T; Hundsdörfer P; Misch D; Steffen IG; Schönberger S; Furth C; Plotkin M; Ruf J; Hautzel H; Stöver B; Kluge R; Bierbach U; Otto S; Beck JF; Franzius C; Henze G; Amthauer H Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1842-53. PubMed ID: 20505933 [TBL] [Abstract][Full Text] [Related]
28. [Value of Pretherapeutic Ding CY; Liu HY; Guo Z; Li TN Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):438-443. PubMed ID: 28446289 [TBL] [Abstract][Full Text] [Related]
29. Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors. Sugihara T; Koizumi M; Koyama M; Terauchi T; Gomi N; Ito Y; Hatake K; Sata N Ann Nucl Med; 2017 Dec; 31(10):719-725. PubMed ID: 28864931 [TBL] [Abstract][Full Text] [Related]
30. ¹⁸F-FDG PET/CT in hepatocellular carcinoma: detection of bone metastasis and prediction of prognosis. Seo HJ; Kim GM; Kim JH; Kang WJ; Choi HJ Nucl Med Commun; 2015 Mar; 36(3):226-33. PubMed ID: 25460306 [TBL] [Abstract][Full Text] [Related]
31. Dual-phase F-18 FDG PET-CT in staging and lymphoscintigraphy for detection of sentinel lymph nodes in oral cavity cancers. Sürücü E; Polack BD; Demir Y; Durmuşoğlu M; Ekmekçi S; Sarıoğlu S; Çelik AO; Ada E; İkiz AÖ Clin Imaging; 2015; 39(5):781-6. PubMed ID: 25721710 [TBL] [Abstract][Full Text] [Related]
32. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824 [TBL] [Abstract][Full Text] [Related]
34. Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas. Kitao T; Shiga T; Hirata K; Sekizawa M; Takei T; Yamashiro K; Tamaki N Ann Nucl Med; 2019 Jan; 33(1):22-31. PubMed ID: 30196378 [TBL] [Abstract][Full Text] [Related]
35. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies. Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571 [TBL] [Abstract][Full Text] [Related]
36. Diagnostic value of Kassem TW; Abdelaziz O; Emad-Eldin S Diagn Interv Imaging; 2017 Oct; 98(10):693-698. PubMed ID: 28734778 [TBL] [Abstract][Full Text] [Related]
37. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer. Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586 [TBL] [Abstract][Full Text] [Related]
38. [Evaluation of bone scintigraphy and (18)F-FDG PET/CT in bone metastases of lung cancer patients]. Portilla-Quattrociocchi H; Banzo I; Martínez-Rodríguez I; Quirce R; Jiménez-Bonilla J; de Arcocha Torres M; Medina-Quiroz P; del Castillo R; Rubio-Vassallo A; Carril JM Rev Esp Med Nucl; 2011; 30(1):2-7. PubMed ID: 21208693 [TBL] [Abstract][Full Text] [Related]
39. Role of FDG-PET in the assessment of survival prognosis in melanoma. Pleiss C; Risse JH; Biersack HJ; Bender H Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764 [TBL] [Abstract][Full Text] [Related]
40. Combination of FDG PET/CT and contrast-enhanced MSCT in detecting lymph node metastasis of esophageal cancer. Tan R; Yao SZ; Huang ZQ; Li J; Li X; Tan HH; Liu QW Asian Pac J Cancer Prev; 2014; 15(18):7719-24. PubMed ID: 25292052 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]